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Background: Although logical in theory, the efficacy and safety of enoxaparin bridging (EB) in patients with nonvalvular atrial fibrillation (NAF), 
compared to simply withholding warfarin without EB, has yet to be determined. We sought to clarify this issue by analyzing our own ten year 
experience with perioperative anticoagulation management in patients with NAF.
Methods: Of 2,687 patients on warfarin therapy screened, 513 had warfarin stopped for 727 separate invasive procedures. Of these procedures, 
356 were performed in patients taking warfarin to prevent embolic stroke in NAF. For 50 of these procedures, patients were bridged with enoxaparin 
and for the remaining 306 procedures, warfarin was withheld without EB. The decision to bridge a patient or not was solely at the discretion of the 
managing physician, hence the observational nature of this study. We compared adverse periprocedural events in the bridged versus nonbridged 
groups using a two-tailed Chi Square test. 
Results: There occurred 31 total periprocedural complications, 20 hemorrhagic and 11 thromboembolic in nature. In addition, 11 complications 
were classified as major in severity and 20 as minor. The comparison of complications between bridged and nonbridged groups is shown in TABLE.
Conclusions: In this retrospective study, EB in patients with NAF, compared to stopping warfarin without EB, did not lessen periprocedural 
thromboembolic complications, either major or minor, and was associated with a higher incidence of major bleeding.
Periprocedural Complications in Bridged versus Non-Bridged Groups
Non-Bridged Procedures 
(n=306)
Bridged Procedures (n=50) P value
Total Complications (n=31) 27 (8.8%) 4 (8.0%) 0.848
Hemorrhagic Complications (n=20) 18 (5.9%) 2 (4.0%) 0.592
Thromboembolic Complications (n=11) 9 (2.9%) 2 (4.0%) 0.688
Major Complications (n=11) 7 (2.3%) 4(8.0%) 0.031
Major Hemorrhagic (n=3) 1 (0.3%) 2 (4.0%) 0.008
Major Thromboembolic (n=8) 6 (2.0%) 2 (4.0%) 0.367
Minor Complications (n=20) 20 (6.5%) 0 (0%) 0.063
Minor Hemorrhagic (n=17) 17 (5.6%) 0 (0%) 0.088
Minor Thromboembolic (n=3) 3 (1.0%) 0 (0%) 0.482
